يعرض 1 - 20 نتائج من 95 نتيجة بحث عن '"Wierda WG"', وقت الاستعلام: 0.69s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal

    المصدر: Leukemia. 30(4)

    وصف الملف: application/pdf

  12. 12
    Academic Journal
  13. 13
    Academic Journal

    Relation: pii: S0006-4971(22)00246-4; Tam, C. S., Allan, J. N., Siddiqi, T., Kipps, T. J., Jacobs, R., Opat, S., Barr, P. M., Tedeschi, A., Trentin, L., Bannerji, R., Jackson, S., Kuss, B. J., Moreno, C., Szafer-Glusman, E., Russell, K., Zhou, C., Ninomoto, J., Dean, J. P., Wierda, W. G. & Ghia, P. (2022). Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD, 139 (22), pp.3278-3289. https://doi.org/10.1182/blood.2021014488.; http://hdl.handle.net/11343/301630

  14. 14
    Academic Journal

    Relation: pii: 707537; Barr, P. M., Tedeschi, A., Wierda, W. G., Allan, J. N., Ghia, P., Vallisa, D., Jacobs, R., O'Brien, S., Grigg, A. P., Walker, P., Zhou, C., Ninomoto, J., Krigsfeld, G. & Tam, C. S. (2022). Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts. CLINICAL CANCER RESEARCH, 28 (20), pp.4385-4391. https://doi.org/10.1158/1078-0432.CCR-22-0504.; http://hdl.handle.net/11343/320162

  15. 15
    Academic Journal
  16. 16
    Academic Journal

    Relation: pii: 1078-0432.CCR-20-4842; Davids, M. S., Roberts, A. W., Kenkre, V. P., Wierda, W. G., Kumar, A., Kipps, T. J., Boyer, M., Salem, A. H., Pesko, J. C., Arzt, J. A., Mantas, M., Kim, S. Y. & Seymour, J. F. (2021). Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. CLINICAL CANCER RESEARCH, 27 (17), pp.4690-4695. https://doi.org/10.1158/1078-0432.CCR-20-4842.; http://hdl.handle.net/11343/307858

  17. 17
    Academic Journal

    Relation: Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, A., Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, C., Jacobs, R., Pagel, J. M., Flinn, I., Pak, Y., Zhou, C., Szafer-Glusman, E., Ninomoto, J., Dean, J. P., James, D. F. ,. Tam, C. S. (2021). Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. JOURNAL OF CLINICAL ONCOLOGY, 39 (34), pp.3853-+. https://doi.org/10.1200/JCO.21.00807.; http://hdl.handle.net/11343/301618

  18. 18
    Academic Journal
  19. 19
    Conference
  20. 20
    Academic Journal

    Relation: Jones, J., Mato, A., Coutre, S., Byrd, J. C., Furman, R. R., Hillmen, P., Osterborg, A., Tam, C., Stilgenbauer, S., Wierda, W. G., Heerema, N. A., Eckert, K., Clow, F., Zhou, C., Chu, A. D., James, D. F. & O'Brien, S. M. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials. BRITISH JOURNAL OF HAEMATOLOGY, 182 (4), pp.504-512. https://doi.org/10.1111/bjh.15421.; http://hdl.handle.net/11343/271068